Week In Review: How Trump's Policies Moved Stocks - Saturday, May 23

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump and his administration with this weekly recap compiled by The Fly.

COVID-19 VACCINE

On Thursday, AstraZeneca stated that it is collaborating with a number of countries and multilateral organizations to make the University of Oxford's COVID-19 vaccine "widely accessible around the world in an equitable manner." The company has concluded the first agreements for at least 400M doses and has secured total manufacturing capacity for one billion doses so far and will begin first deliveries in September 2020.

AstraZeneca also announced that it received support of more than $1B from the U.S. Biomedical Advanced Research and Development Authority for the development, production and delivery of the vaccine, starting in the fall.

On Friday, Reuters reported that the U.S. is planning a "massive testing effort" as a vaccine is sought to fight COVID-19. The plans involve more than 100,000 volunteers and a half dozen or so of "the most promising vaccine candidates" with a goal of finding a safe and effective one by the end of 2020. On the "short list," a Moderna (MRNA) vaccine will be the first to the enter large-scale testing in July, and it could be joined by the vaccine from Oxford University and AstraZeneca, according to Francis Collins, the director of the National Institutes of Health. Vaccines by Johnson & Johnson (JNJ), Sanofi (SNY) and Merck (MRK), which are "a month or two behind the frontrunners," may get added over the course of the summer, the report added.

2ANTI-MALARIA DRUG

President Trump said that he has been taking anti-malaria drug hydroxychloroquine for more than a week to prevent himself from contracting coronavirus infection, according to CNBC.

On Friday, the Washington Post's Ariana Eunjung Cha and Laurie McGinley reported that a study published in medical journal the Lancet concluded that the anti-malaria drug that President Trump has said that he has been taking has been linked to a significantly higher risk of death and patients taking it were also more likely to develop a type of irregular heart rhythm that can lead to sudden cardiac death.

1 2 3
View single page >> |

Disclosure: None.

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Chee Hin Teh 4 months ago Member's comment

Well said. Many thanks. James